Issue link:

Contents of this Issue


Page 27 of 31

Including events rescheduled due to COVID-19, the calendar provides a list of upcoming conferences, workshops and educational events, with dates, locations and web links for more information and registration. June 2020 Inhalation that dates may change further, so stay in touch with the organizers. July Inhalation & Respiratory Drug Delivery UK (Virtual). July 8-9, 2020. https://www.oxfordglobal. September Pulmonary Drug Delivery. Sep- tember 2-4, 2020 in Dublin, Ireland. www.pulmonar ydrug Metered Dose Inhaler Technol- ogy. September 16-17, 2020 in London, UK. https://manage Aerosol School. Canceled for 2020. Please check for updates. Inhalation & Respiratory Drug Delivery Congress US (Virtual). September 29-30, 2020. https:// October Drug Deliver y Partnerships. October 12-14, 2020 in Orlando, FL, US. http://informaconnect. com/ddp Association of Inhalation Toxi- cologists. To be replaced for 2020 by online lectures. https://www. MVIS Symposium & Workshop. October 19-22, 2020 in Lund, Swe- den. AAPS PharmSci360. October 25-28, 2020 in New Orleans, LA, US. November Inhaled Drug Delivery. Novem- ber 3-4, 2020 in London, UK. RDD Asia 2020. November 4-6, 2020 in Goa, India. https://www. December The Christmas Lectures (Vir- tual). (Replaces Drug Delivery to the Lungs 2020.) December 9-11, 2020. https://ddl- GmbH announced an exclusive partnership to develop mRNA- e n c o d e d , n e u t r a l i z i n g a n t i - SARS- CoV-2 antibodies to be administered by inhalation for treatment of COVID-19. Neurim- mune is identifying human anti- SARS-CoV-2 antibodies from the immune cells of recovered COVID-19 patients using its RT M ™ t e c h n o l o g y p l a t f o r m . Potent neutralizing antibodies will be translated into therapeu- tic products for inhalation using Ethris' proprietary pulmonary SNIM ® RNA technology. The companies noted that production of specific, neutralizing antibodies directly in patients' lungs provides the opportunity to significantly impact the viral lung disease that is the primary driver of morbid- ity and mortality. The planned treatment could be effective in all COVID-19 patients. The com- panies plan to begin manufactur- ing the drug product for clinical trials in the summer of 2020. e first candidate is expected to begin clinical testing in the fourth quar- ter of 2020, pending regulatory approval. Ethris focuses on deliv- ery of mRNA directly to the respi- ratory system by nebulization and the company collaborates with AstraZeneca in asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. FDA grants Bellerophon emergency expanded access for COVID-19 treatment WA R R E N , N EW J E R S EY — According to Globe Newswire, Bellerophon Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has granted emergency expanded access allowing its pro- prietary inhaled nitric oxide (iNO) delivery system, INOpulse ® , to immediately be used for the treat- ment of COVID-19. A company news release explained that "NO is a naturally produced molecule that is critical to the immune response against pathogens and infections. In vitro studies have shown that it inhibits replication of severe acute respiratory syndrome-related coronavirus (SARS-CoV) and improves survival for cells infected with SARS-CoV. In a clinical study of patients infected with SARS- CoV, iNO demonstrated improve- ments in arterial oxygenation, a reduction in the need for venti- lation support and an improve- ment in lung infiltrates observed on chest radiography. Based on the genetic similarities between the two coronaviruses, the data in SARS-CoV support the poten- tial for iNO to provide meaning- ful benefit for patients infected with COVID-19." Further, Fabian Tenenbaum, Chief Executive Offi- cer of Bellerophon, noted that "INOpulse is designed to treat patients in the outpatient setting, which may be critical in helping combat the further spread of the virus and significantly alleviate the mounting impact on hospitals and intensive care units." Calendar As of May 19, the following events have been revised or rescheduled due to COVID-19 or are scheduled as initially planned. Please be aware advertiser index A Astech 7 C Catalent Pharma Solutions Cover 2 Cliantha Research 17 Copley Scientific 3 E Experic 9 M Merxin Ltd. 8 MSP 1 P Presspart Manufacturing Ltd 11 Proveris 15 Q Qualicaps 25 R RDD Cover 3 Recipharm 5

Articles in this issue

Links on this page

view archives of Inhalation - INH0620